Management of COVID-19 in people with epilepsy: drug considerations

被引：39

作者：

Asadi-Pooya, Ali A. ^{[1
,2
]}

Attar, Armin ^{[3
]}

Moghadami, Mohsen ^{[4
]}

Karimzadeh, Iman ^{[5
]}

机构：

[1] Shiraz Univ Med Sci, Epilepsy Res Ctr, Shiraz, Iran

[2] Thomas Jefferson Univ, Dept Neurol, Jefferson Comprehens Epilepsy Ctr, Philadelphia, PA 19107 USA

[3] Shiraz Univ Med Sci, Dept Cardiovasc Med, Shiraz, Iran

[4] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran

[5] Shiraz Univ Med Sci, Dept Clin Pharm, Shiraz, Iran

来源：

NEUROLOGICAL SCIENCES | 2020年 / 41卷 / 08期

关键词：

Antiepileptic drug; COVID; Epilepsy; Interaction; Seizure; CONDUCTION;

D O I：

10.1007/s10072-020-04549-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interactions could pose significant challenges and cardiac, hepatic, or renal problems, which may happen in patients with severe COVID-19, may require adjustment to antiepileptic drugs (AEDs). In this review, we first summarize the potential drug-drug interactions between AEDs and drugs currently used in the management of COVID-19. We then summarize other challenging issues that may happen in PWE, who have COVID-19 and are receiving treatment.

引用

页码：2005 / 2011

页数：7

共 22 条

[1]

Asadi-Pooya A.A., 2016, ANTIEPILEPTIC DRUGS

[2] Central nervous system manifestations of COVID-19: A systematic review [J].